Put Arrhythmia Warnings for Lamotrigine in Context
June 2021
A new FDA warning will spur questions about the risk of serious arrhythmias with lamotrigine (Lamictal).
Labeling now cautions to weigh lamotrigine risks and benefits in patients with ischemic CV damage (prior MI, etc)...structural or functional disease (heart failure, AV block, etc)...or multiple CV risks.
It stems from lab data showing that lamotrigine’s effects on cardiac sodium channels could widen the QRS interval...and from case reports linking lamotrigine to ECG changes or cardiac arrest.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote